1 / 2

Flexible manufacturing for vaccines – helping Novartis Vaccines to improve competitiveness

Flexible manufacturing for vaccines – helping Novartis Vaccines to improve competitiveness. EUR 2.3 M project value. Solutions implemented: PCS-7 batch-based process control system Motor controls, UPS, weighing system Building management system

ansel
Download Presentation

Flexible manufacturing for vaccines – helping Novartis Vaccines to improve competitiveness

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Flexible manufacturing for vaccines – helping Novartis Vaccines to improve competitiveness EUR 2.3 Mproject value Solutions implemented: • PCS-7 batch-based process control system • Motor controls, UPS, weighing system • Building management system • A&D S7 PLCs specified to all 3rd party equipment suppliers • Novartis Vaccines is the world's fifth-largest vaccines business and the world's second-largest manufacturer of flu vaccines and has important meningococcal, pediatric and travel vaccine franchises. The company's portfolio of products includes vaccines for influenza, meningitis, rabies, tick-borne encephalitis, Haemophilus influenzae B (Hib), polio, mumps, measles and rubella and diphtheria, tetanus and pertussis (whooping cough). • The site at Liverpool, which has a long history, was selected for a major investment to develop a state-of-the-art manufacturing facility for flexible vaccine production. The new building is known as ‘Site 4’. Siemens Groups involved: • A&D & SBT • Future potential for A&D, SBT and Enterprise • Project goal: • Initially, to increase the output and quality of flu vaccine production. • In the long term, Site 4 will be Novartis’s main site for the production of egg-based vaccines • Value to customer: • Siemens has worked as a team with Novartis and the engineering contractor, CEL International, to ensure that Site 4 will be capable of meeting its quality and production requirements • Understanding Novartis’s business drivers has been a key factor • The future: • Expansion of the initial facility is planned, with significant A&D potential • Enterprise are in discussions with Novartis Vaccines regarding global voice and data requirements • SBT are also in discussions regarding managed security on site

  2. Back-up InformationSiemens GBR: Chiron Vaccines Limited Customer Information • Customer Name: Novartis Vaccines & Diagnostics Limited • Location: Liverpool / UK • Siemens Contact Persons: Harald / Rueckl / harald.rueckl@novartis.com • Project completion: First phase completion March 2007 Organizational Topics • Cleared for external use: no • Use of picture and logo: no • Existing material: Internal presentation attached • Sector/solution: Pharmaceutical • Further notes…

More Related